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Abstract
Background: Dignity Therapy is a brief psychotherapy that can enhance a sense of legacy while addressing the
emotional and existential needs of patients receiving hospice or palliative care. In Dignity Therapy, patients create a
formalized “legacy” document that records their most cherished memories, their lessons learned in life, as well as
their hopes and dreams for loved ones in the future. To date, this treatment has been studied for its impact on
mitigating distress within hospice and palliative care populations and has provided mixed results. This study will
instead focus on whether Dignity Therapy enhances positive outcomes in this population.
Methods/Design: In this study, 90 patients with cancer receiving hospice or palliative care will complete a mixed-
methods randomized controlled trial of Dignity Therapy (n = 45) versus Supportive Attention (n = 45). The patients will be
enrolled in the study for 3 weeks, receiving a total of six study visits. The primary outcomes examine whether the
treatment will quantitatively increase levels of positive affect and a sense of life closure. Secondary outcomes focus on
gratitude, hope, life satisfaction, meaning in life, resilience, and self-efficacy. Using a fixed, embedded dataset design, this
study will additionally use qualitative interviews to explore patients’ perceptions regarding the use of positive outcome
measures and whether these outcomes are appropriately matched to their experiences in therapy.
Discussion: Dignity Therapy has shown mixed results when evaluating its impact on distress, although no other study to
date has solely focused on the potential positive aspects of this treatment. This study is novel in its use of mixed methods
assessments to focus on positive outcomes, and will provide valuable information about patients’ direct experiences in
this area.
Trial registration: ISRCTN91389194
Keywords: Cancer care, Hospice care, Palliative care, Dignity therapy, End-of-life care, Life satisfaction, Quality of life,
Positive outcomes
Background
Caring for cancer patients in hospice or palliative care
involves addressing many physical, psychological, social,
and spiritual concerns [1–4]. In doing so, there is often
a two-fold mission: 1) decreasing suffering and distress
while 2) increasing positive quality of life [5, 6]. For
example, in order to address the psychological concerns
of cancer patients receiving hospice or palliative care,
several psychotherapies have been created and studied
[2, 7–12].
One such therapy is Dignity Therapy; a brief, individu-
alized psychotherapy designed to address the emotional
and existential needs of adults who are receiving hos-
pice or palliative care while enhancing a sense of legacy
[13–17]. In therapy, patients complete an interview that
highlights their most important memories, the times
they felt most alive, and their most important accomplish-
ments and roles. Additionally, patients are able to reflect
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on the lessons they have learned in life, and describe any
hopes and dreams they have for their loved ones in the fu-
ture. This interview is recorded, transcribed, and edited to
create a formalized “legacy document” which can then be
given to the patient’s family and friends as a keepsake.
The first Phase I trial of Dignity Therapy with 100
patients demonstrated significant decreases in depressive
symptoms and patients’ sense of suffering at post-
treatment, with the majority of patients reporting an
increased sense of dignity (76 %), sense of purpose
(68 %), and sense of meaning (67 %) [15]. A subse-
quent study of 60 family members, whose loved ones
had completed Dignity Therapy, resulted in similar
trends, providing corroboration that the treatment
was viewed favorably and was highly recommended as
a treatment for others [18].
The most recent Phase III randomized controlled trial
of Dignity Therapy compared patients who received
Dignity Therapy (n = 108), Client Centered Care (n =
107), and Standard Care (n = 111) on the primary out-
comes of distress [19]. Interestingly, no significant dif-
ferences were found between the 3 treatment groups
on the primary measures of distress. However, on sec-
ondary measures the Dignity Therapy patients reported
significantly higher ratings regarding the treatment be-
ing helpful, improving quality of life, increasing a sense
of dignity, being beneficial to the family, and changing
the way the family appreciated the patient. In light of
the mixed results, the researchers noted the study in-
struments may have been unresponsive to the beneficial
changes demonstrated in the Dignity Therapy group.
As such, the researchers concluded that “future re-
search exploring the beneficial effects of Dignity Ther-
apy will help unravel the psychological, spiritual, and
existential complexities for an individual facing
death…” (p. 9).
We began to explore the beneficial effects of Dignity
Therapy at San Diego Hospice and the Institute for
Palliative Care in 2009. In this environment, we provided
Dignity Therapy as a clinical service to patients with
cancer and other diagnoses, serving as the first hospice
in the country to do so. As a result, we gathered valuable
pilot data regarding the referral processes, logistics, and
basic costs of treatment as well as the characteristics of
patients who completed Dignity Therapy [20]. We add-
itionally gathered pilot data from 23 patients, 7 family
members, and 18 hospice staff who were asked to rate
the treatment. All three groups rated Dignity Therapy as
“highly worthwhile” and “helpful.” During additional
qualitative interviews, the staff did not frequently describe
Dignity Therapy as a tool to mitigate distress, but spoke
more often about it as a positively enhancing experience;
one that provided a valuable sense of contentment, grati-
tude, hope, meaning, and resilience for patients as well as
a way to address unfinished business and create a sense of
connectedness among the patients, families, and friends
[21].
Overall, the results of the previous randomized con-
trolled trials as well as our pilot studies suggest that
Dignity Therapy can provide positive benefits, although
these outcomes have not been systematically investigated
to date. Therefore this study is designed to measure the
positive impact of enhancing legacy via Dignity Therapy
among patients with cancer receiving hospice or
palliative care. Specifically, this study aims to examine
whether Dignity Therapy can significantly increase
positive outcomes such as contentment, gratitude,
hope, meaning, positive affect, satisfaction with life,
and a sense of life closure. An additional line of
inquiry is whether patients’ levels of resilience and
self-efficacy play a mediating or moderating role in the
treatment’s impact.
Moreover, patients in this study will be asked to share
their direct experience with the therapy, and will be
asked to provide their feedback about the applicability of
positive outcome measures. Using a mixed-methods
design, the study incorporates quantitative treatment
outcomes in addition to qualitative data regarding
patients’ perceptions. These results can guide future
positive outcome research, particularly as we aim to
design studies that fit patients’ needs.
Methods and design
This study involves a mixed-methods randomized con-
trolled trial of Dignity Therapy versus a Supportive
Attention control group (please see Fig. 1 for an over-
view of the study activities). Specifically, this study
involves providing either Dignity Therapy or Supportive
Attention to 90 patients receiving hospice or palliative
care who have a primary diagnosis of cancer. The aim
is to assess whether patients who receive Dignity Ther-
apy will exhibit significantly greater contentment, hope,
gratitude, positive affect and sense of closure, and
whether patients’ levels of resilience and self-efficacy
mediate or moderate this effect.
All of the patients in the study will be followed for
14 days, with evaluations occurring at baseline and at
the end of treatment. Each hour-long therapy session
also includes the administration of two brief assess-
ments related to positive affect and life satisfaction to
explore whether each session provides some level of
beneficial effect (please see Table 1 for a list of the
study assessments and schedule). This study protocol
and all accompanying materials have been approved
by the University of California, San Diego Institu-
tional Review Board and Human Research Protections
Program.
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Study sample
This study will sample 90 cancer patients receiving
hospice or palliative care. These 90 participants will
be randomized to either Dignity Therapy (n = 45) or
Supportive Attention (n = 45). Of the 45 patients
completing the Dignity Therapy, 25 randomly-selected
participants will be asked to complete qualitative
interviews regarding their perspectives on the treat-
ment as well as the study’s use of positive outcomes.
Inclusion criteria
 Primary diagnosis of cancer
 Age ≥ 18
 Enrolled in hospice or palliative care
 Willing and able to give informed consent to
participate
 Able to speak and understand English
 Able to sustain attention and effort for
approximately 1 hour of interaction
Exclusion criteria
 Current diagnosis of severe dementia, delirium, or
other cognitive impairment
 Unable to speak and understand English
After providing informed consent, patients will be
randomly assigned to the Dignity Therapy or a Support-
ive Attention Control group. All patients will continue
Fig. 1 Study flow-chart of the randomized controlled trial of Dignity Therapy focused on positive outcomes
Table 1 Study outcomes and assessment schedule for the randomized controlled trial of Dignity Therapy focused on positive
outcomes
Instrument Time in minutes Baseline Session 1 Session 2 Session 3 Session 4 Post-Test
Positive and Negative Affect Scale (PANAS) 5 • • • • • •
Life Closure Scale (LCS) 10 • •
Hearth Hope Index (HHI) 5 • •
Satisfaction with Life (BPFSS) 3 • • • • • •
Gratitude Questionnaire (GQ-6) 5 • •
Connor-Davidson Resilience Scale (CD-RISC) 7 • •
Hospital Anxiety and Depression Scale (HADS) 5 • •
Life Evaluation Questionnaire (LEQ) 10 • •
Self-Efficacy (GSE) 5 • •
Study Completion Questionnaire 5 •
TOTAL 70 10 10 10 10 75
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to receive standard hospice or palliative care with their
usual physicians and care teams during the trial. This
includes access to social workers and spiritual coun-
selors if desired for any psychosocial distress.
Study treatments
Dignity Therapy
Dignity Therapy is a brief, empirically-supported, indi-
vidualized psychotherapy designed for adults receiving
hospice or palliative care. In this study, the therapy will
be performed by trained Master’s level mental health
counselors who will meet with patients during 4 home-
based visits over the course of 3 weeks, each session
lasting approximately 1 hour. The first session will
involve a consultation to evaluate the patient’s motiv-
ation for therapy and to determine any specific goals
they have for creating the legacy document. The
second session will involve the completion of a life
reflection interview using the standardized interview
protocol [13, 15, 17, 19]. The life reflection interview
will be digitally recorded, transcribed, and edited.
In the third session, the typewritten document will be
read to the patient in its entirety. This session fosters
autonomy by allowing the patient to provide personal
edits as necessary, and ensures accuracy of content.
Additional therapeutic value is gained since the reading
provides an emotional reminder of the patient’s cher-
ished memories and verifies that his/her history has been
witnessed and recorded according to his/her wishes. The
final session will then be conducted after all of the
patient’s edits have been completed and formatted into a
bound document. In this session a hard-copy version of
the “legacy” document will be given to the patient and
provided for dissemination to loved ones as a keepsake if
desired.
Supportive attention
Patients assigned to the Supportive Attention control
group will be paired with a trained Master’s level mental
health counselor. These counselors will provide atten-
tion, a compassionate presence, and address any of the
patient’s here-and-now concerns, but will not focus on
enhancing a sense of legacy. In order to mirror the Dignity
Therapy treatment, patients in Supportive Attention will
also receive 4 one-hour sessions, each provided in the
home, with all treatments being completed over the
course of 3 weeks.
Study outcomes
This trial will focus on the measurement of positive
outcomes related to Dignity Therapy. All tests will be
administered according to published standardized pro-
cedures by raters trained to a high level of inter-rater
reliability (≥0.90). The tests in the battery were selected
with several factors in mind: (a) validity and reliability; (b)
relevance to the literature and prior experience with these
tests in previous studies; and (c) limiting the length of the
battery to a total of 70 minutes or less in order to reduce
fatigue and undue burden for patients.
Primary outcome measures
Positive and Negative Affect The Positive and Negative
Affect Schedule (PANAS) will be used to quantify
affective states. The PANAS is a 20-item self-report
measure with 10 positive items and 10 negative items,
thereby allowing for simultaneous measures of both
positive and negative states among patients in the study.
Higher scores on the 10 items in the Positive Affect
scale will indicate pleasurable engagement and satisfac-
tion with the environment, and higher scores on the
Negative Affect scale will indicate anxiety, disengage-
ment, distress, and dysfunction.
Patients will rate their agreement with emotional
adjectives such as “Interested” or “Scared” on a Likert
scale from 1 to 5 (1 = very slightly or not at all; 5 = ex-
tremely). The instrument will be used to measure
treatment effects within a session as well as overarch-
ing measurements of change before and after the full
intervention [22, 23].
Life Closure The Life Closure Scale (LCS) is a 20-item
scale to assess psychological adaptation and psycho-
logical well-being in patients at the end of life. The
LCS contains two factor-analyzed subscales: Content-
ment and Contention. On the LCS, patients will
report their level of agreement with statements using
a 5-point Likert scale items such as “I can find some-
thing cheerful to think about”, “I have happy memor-
ies to help me”, or “Nothing has worked out right for
me” [24].
Secondary outcome measures
Depression and anxiety The Hospital Anxiety and
Depression Scale (HADS) is a 14-item self-report
measure of the relative frequency of depressed and
anxious symptoms over the past week. Patients will
rate items such as “I feel tense or wound up” and “I
feel as if I am slowed down” on a 4-point Likert scale
ranging from 0 to 3 (0 = not at all; 3 = very often) [25, 26].
Gratitude The Gratitude Questionnaire Six-Item Form
(GQ-6) is a brief scale designed to measure peoples’
experience of gratitude, forgiveness and spiritual tran-
scendence. Patients will report their level of agreement
with statements using a 7-point Likert scale (1 = Strongly
Disagree; 7 = Strongly Agree). Sample items include: “As
I get older I find myself more able to appreciate the
people, events, and situations that have been part of my
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life history,” and “I have so much in life to be thankful
for” [27].
Hope The Hearth Hope Index (HHI) is a 12-item scale
to assess levels of hope among people with life-
threatening illnesses with items such as “I have plans for
the future” and “I believe each day has potential.” Scores
range from 12 to 48, with higher scores denoting greater
hope. The HHI contains 3 factors assessing 1) temporal-
ity and future, 2) inner positive readiness and expect-
ancy, and 3) interconnectedness [28].
Meaning in Life The Life Evaluation Questionnaire
(LEQ) is a 44-item measure of how patients with incur-
able cancer reflect upon their lives. Sample items
include: “On the whole, life has treated me well,” and
“Something good has come out of my illness.” The LEQ
contains five subscales: freedom versus restriction, ap-
preciation of life, contentment, resentment, and social
integration. The 5-item Appreciation of Life subscale,
the 8-item Contentment subscale and the 8-item Social
Integration subscale will be used in this study [29].
Resilience The Connor-Davidson Resilience Scale (CD-
RISC) is comprised of 25 items using a 5-point Likert
scale. The CD-RISC measures how people have felt in
the past month, and scores range between 0 and 100;
higher scores indicating greater resilience. Sample items
include: “I tend to bounce back after illness, injury, or
other hardships,” and “I give my best effort no matter
what the outcome may be.” The items pertain to
concepts such as personal competence, a tolerance of
negative affect, a positive acceptance of change, and
tenacity. This scale is used to identify whether resilience
is a mediating or moderating variable among patients in
the study [30].
Satisfaction with life The Behavioral Risk Factor Sur-
veillance System (BRFSS) Questionnaire was established
in 1984 by the Centers for Disease Control and Preven-
tion (CDC). The questions in this interview are now
asked of more than 350,000 adults per year in all 50 U.S.
states. One item within the BRFSS pertains to overall
satisfaction with life. Patients in this study will state their
level of agreement with this item that asks, “In general,
how satisfied are you with your life?” [31].
Self-efficacy The General Self-Efficacy Scale (GSE) is a
10-item scale measuring optimistic self-beliefs such as
coping with adversity, persistence, or the ability to
perform difficult tasks. Scores range from 10 to 40 using
a 4-point scale (1 = not at all true; 4 = exactly true).
Sample items include, “I can usually handle whatever
comes my way” and “When I am confronted with a
problem, I can usually find several solutions.” This scale
is used to identify whether self-efficacy is a mediating or
moderating variable for patients in the study [32].
Study completion questionnaire To gather patient
feedback regarding the impact of the therapy sessions, a
researcher-derived questionnaire has been created for
this study. The questionnaire contains 30 brief Likert-
scale items for patients to rate, at the completion of the
study, whether the treatment they received (either
Dignity Therapy or Supportive Attention) was helpful,
worthwhile, and enhanced their sense of personhood.
Sample items include, “Participating in this study has
helped me feel like a person, not just a disease,” and
“The process of completing this study was worthwhile.”
Qualitative interview
As part of this study’s mixed-methods design, a randomly-
selected subset of Dignity Therapy patients will complete
a qualitative interview in addition to the quantitative mea-
sures described above. This one-hour qualitative interview
will include 7 semi-structured questions asking patients
for feedback regarding their Dignity Therapy experience -
what worked, what did not, and what may have surprised
them about the process. Patients will also be asked
whether measuring positive outcomes is “in sync” with
their experience. To this end, sample questions from the
qualitative interview include: “When future researchers
are interested in these types of ‘positive changes,’ what
types of questions would you suggest they ask?” and “In
your opinion, were there positive or negative changes we
should have asked about as you completed your legacy
document, but did not?” These data will help shape future
positive outcome studies – ones that can be based directly
on patients’ perspectives in hospice and palliative care.
Statistical analyses
Descriptive statistics will be obtained for all variables, in-
cluding distributions, means, medians, variances, stand-
ard deviations, skewness, kurtosis, ranges, and quartiles.
Tests of normality of continuous measures will be made
using the Shapiro-Wilk W and the Kolomogorov D
statistics in conjunction with plots of the distribution of
data and descriptive measurements. The data will also
be examined for homogeneity of variance. An appro-
priate statistical method will be employed to correct
for any abnormalities (such as log, square root, and
inverse). All statistical tests will be two-tailed. Differ-
ences will be considered statistically significant pro-
vided a p-value ≤ 0.05 is obtained. The comparability
of the two treatment groups in baseline demographic
and clinical features will be tested with analyses of
variance (ANOVAs) for continuous variables and Chi-
square analyses for dichotomous variables.
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Analyses will be based on a Random Regression
Model (RRM) for continuous data using a generalized
linear model [33, 34]. This model was selected over
more traditional analytic approaches such as a change
score, end-point, or repeated measures analysis of vari-
ance for several reasons. First, a 14–20 % death rate is
anticipated based on pilot studies, and using this statis-
tical method, we will be able to include all of the pa-
tients with missing data, early termination, or death
without relying on data imputation procedures. Second,
both fixed and time-varying covariates and systematic
person-specific deviations from the average time trend
are allowed in this method. A fully saturated treatment
by time model will be utilized for inference. Co-
variance structure will be chosen based on Akaikes In-
formation Criterion (AIC). Random group level treat-
ment effects will also be evaluated for importance based
on the model AIC. This allows for any group level effects
to be incorporated into the model. Denominator degrees
of freedom will be calculated using the Kenward-Roger
small sample correction.
In order to assess how resilience and self-efficacy may
mediate or moderate the impact of Dignity Therapy, we
will use a RRM method similar to the primary hypoth-
eses. The effect of mediator and moderator variables will
be explored using RRM for each candidate mediator and
moderator as a main effect and an interaction [35, 36]. If
the interaction effect is significant, pairwise comparisons
of groups will be performed. These analyses will examine
interactions of treatment group with time at each level
of the mediator and moderator, and evaluate treatment
levels within each subgroup.
Finally, the time course of treatment of each individual
will be modeled by projecting the outcome measures on
orthogonal linear, and quadratic of time. Model diag-
nostics will be used to determine the suitability of an
autoregressive error component and nonlinear effects
for assessment time. Analyses will be performed using
the SPSS (version 21.0) procedures. Data will be
included for all patients completing at least one assess-
ment after baseline.
The assumptions for sample size and power calcula-
tion are based on our pilot data and using procedures
described by Hedeker et al. for Random Regression
Models (RRM) [37]. With the proposed sample size of
86 subjects without attrition or 90 subjects adjusted for
attrition (45 for each of the two groups), the study will
have power of 80 % to yield a statistically significant
result for a medium effect size. Here, medium effect size
is defined as a between-group difference increasing lin-
earity from 0 at baseline to 0.5 SD units at session 4. Re-
sults from this study will provide information regarding
appropriate power calculations to further determine ne-
cessary effect sizes for larger-scale studies in the future.
Qualitative analyses
Using a methodology of Coding Consensus, Co-occurrence,
and Comparison, rooted in Grounded Theory, a quali-
tative analysis of interviews among 25 randomly-
selected patients completing Dignity Therapy will be
completed [38–40]. These one-hour, semi-structured
interviews will be recorded and transcribed, then two
study investigators will independently read a randomly-
selected 20 % subset of the interview transcripts. The
initial themes present will be discussed and compared.
A coding matrix will then be devised and applied to
subsequent transcripts until saturation is achieved.
Upon saturation, the coding matrix will be applied to
all the study transcripts in their entirety with coding
being completed at the paragraph level. During this
coding process, disagreements in assignment or de-
scription of codes will be resolved through a discussion
between the investigators and an enhanced definition of
codes. A detailed analysis and calculation of the
frequencies of codes and nodal relationships will be
completed using Dedoose software.
Discussion
This study will measure the positive outcomes among
cancer patients in hospice and palliative care who
receive Dignity Therapy versus those who receive
Supportive Attention. Although Dignity Therapy is
designed to address the emotional and existential needs
of patients, little is known about how the treatment may
increase positive aspects such as contentment, gratitude,
hope, meaning, positive affect, sense of closure, and
satisfaction with life.
This study addresses these questions, and utilizes a
novel mixed-method design to additionally gather quali-
tative data regarding patients’ personal experiences with
Dignity Therapy. These qualitative interviews will help
researchers better understand whether positive measures
are viewed as meaningful or relevant to patients, thereby
leading to refined positive outcome studies in the future.
In sum, this study helps address critical questions
pertaining to positive psychotherapeutic outcomes in
cancer care via an emphasis on increasing patients’ sense
of legacy. It has been noted that patients in today’s world
of health care resonate more strongly with how health-
care can enhance their experience and quality of life
versus only focusing on how treatments may diminish
pain or suffering [41]. Randomized controlled trials that
systemically measure the beneficial impacts of treat-
ments are needed now and in the future in order to
fortify the hospice and palliative care response to these
important patients’ needs.
Competing interests
The authors declare that they have no competing interests.
Montross-Thomas et al. BMC Palliative Care  (2015) 14:44 Page 6 of 8
Authors’ contributions
LMT is the study’s principal investigator with oversight of all research
operations. SI is the mentor, having helped conceive of the study and its
implementation with continual assistance in allocating study resources. EM is
the research coordinator overseeing recruitment, training, and study
documentation. JVG is a research assistant and study therapist with roles in
data entry, analysis, and manuscript preparation. SG is the study’s statistician
providing supervision of study design, as well as assistance in data
management and statistical analyses. ER is a collaborating physician
supporting study implementation and recruitment at a palliative care site.
HM is a community partner with contributions to study design and support
for on-going training of study therapists. DM is a grant developer who
helped create the study design, then assisted in writing and submitting the
study grant as well as post-award management. LR is a community partner
who manages all study recruitment and staff needs within a hospice site.
Authors’ information
Not applicable.
Acknowledgements
Work supported by grants from the American Cancer Society: MRSG-13-233-
01-PCSM and the Westreich Foundation (Dr. Lori Montross Thomas), as well
as the National Institute of Mental Health K23MH091176 (Dr. Scott Irwin).
Availability of data and materials
Not applicable.
Author details
1San Diego Moores Cancer Center, Psychiatry & Psychosocial Services; Patient
& Family Support Services, University of California, 9500 Gilman Drive #0664,
La Jolla, San Diego, CA 92093-0664, USA. 2San Diego Department of
Psychiatry, University of California, 9500 Gilman Drive #0664, La Jolla, San
Diego, CA 92093-0664, USA. 3San Diego Department of Family & Preventive
Medicine, University of California, 9500 Gilman Drive #0664, La Jolla, San
Diego, CA 92093-0664, USA. 4University of San Diego, San Diego, USA. 5San
Diego Moores Cancer Center, Doris A. Howell Palliative Care Service,
University of California, San Diego, USA. 6California State University Institute
for Palliative Care, San Diego, USA. 7Family Health Centers of San Diego, San
Diego, USA. 8Mission Hospice, San Diego, USA.
Received: 24 January 2015 Accepted: 7 September 2015
References
1. Chochinov HM, Cann BJ. Interventions to enhance the spiritual aspects of
dying. J Pall Med. 2005;8 Suppl 1:S103–15.
2. Engelberg RA, Downey L, Wenrich MD, MD, Carline JD, Silvestri GA, Dotolo
D, et al. Measuring the quality of end-of-life care. J Pain Symptom Manage.
2010;39(6):951–71.
3. Ferris FD, Balfour HM, Bowen K, Farley J, Hardwick M, Lamontagne C, et al.
A model to guide patient and family care: based on nationally accepted
principles and norms of practice. J Pain Symptom Manage. 2002;24(2):106–
23.
4. Sutton LM, Porter LS, Keefe FJ. Cancer pain at the end of life: a
biopsychosocial perspective. Pain. 2002;99(1–2):5–10.
5. Payne SA, Langley-Evans A, Hillier R. Perceptions of a ‘good’ death: a
comparative study of the views of hospice staff and patients. Palliat Med.
1996;10(4):307–12.
6. Costello J. Dying well: nurses’ experiences of ‘good and bad’ deaths in
hospital. J Adv Nurs. 2006;54(5):594–601.
7. LeMay K, Wilson KG. Treatment of existential distress in life threatening
illness: a review of manualized interventions. Clin Psychol Rev.
2008;28(3):472–93.
8. Breitbart W. Reframing hope: Meaning-centered care for patients near the
end of life. Interview by Karen S. Heller. J Pall Med. 2003;6(6):979–88.
9. Breitbart W, Rosenfeld B, Gibson C, Pessin H, Poppito S, Nelson C, et al.
Meaning-centered group psychotherapy for patients with advanced cancer:
a pilot randomized controlled trial. Psychooncology. 2010;19(1):21–8.
10. Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, et al. Couples
therapy at end of life. Psychooncology. 2003;12(6):620–7.
11. Weaver KE, Llabre MM, Lechner SC, Penedo F, Antoni MH. Comparing
unidimensional and multidimensional models of benefit finding in breast
and prostate cancer. Qual Life Res. 2008;17(5):771–81.
12. Wetherell JL, Sorrell JT, Thorp SR, Patterson TL. Psychological interventions
for late-life anxiety: a review and early lessons from the CALM study. J
Geriatr Psychiatry Neurol. 2005;18(2):72–82.
13. Chochinov HM. Dignity-conserving care–a new model for palliative care:
helping the patient feel valued. JAMA. 2002;287(17):2253–60.
14. Chochinov HM. Dignity and the eye of the beholder. J Clin Oncol.
2004;22(7):1336–40.
15. Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M.
Dignity therapy: a novel psychotherapeutic intervention for patients near
the end of life. J Clin Oncol. 2005;23(24):5520–5.
16. Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M.
Dignity in the terminally ill: a cross-sectional, cohort study. Lancet.
2002;360(9350):2026–30.
17. Chochinov HM. Dignity therapy: Final words for final days. New York: Oxford
University Press; 2012.
18. McClement S, Chochinov HM, Hack T, Hassard T, Kristjanson LJ, Harlos M.
Dignity therapy: family member perspectives. J Pall Med. 2007;10(5):1076–82.
19. Chochinov HM, Kristjanson LJ, Breitbart W, McClement S, Hack T, Hassard T, et
al. Effect of dignity therapy on distress and end-of-life experience in terminally
ill patients: a randomised controlled trial. Lancet Oncol. 2011;12(8):753–62.
20. Montross L, Winters KD, Irwin SA. Dignity therapy implementation in a
community-based hospice setting. J Pall Med. 2011;14(6):729–34.
21. Montross LP, Meier EA, De Cervantes-Monteith K, Vashistha V, Irwin SA. Hospice
staff perspectives on Dignity Therapy. J Pall Med. 2013;16(9):1118–20.
22. Crawford JR, Henry JD. The positive and negative affect schedule (PANAS):
construct validity, measurement properties and normative data in a large
non-clinical sample. Br J Clin Psychol. 2004;43(Pt 3):245–65.
23. Watson D, Clark LA, Tellegen A. Development and validation of brief
measures of positive and negative affect: the PANAS scales. J Pers Soc
Psychol. 1988;54(6):1063–70.
24. Dobratz MC. The life closure scale: Additional psychometric testing of a tool
to measure psychological adaptation in death and dying. Res Nurs Health.
2004;27(1):52–62.
25. Mitchell AJ, Meader N, Symonds P. Diagnostic validity of the Hospital
Anxiety and Depression Scale (HADS) in cancer and palliative settings: A
meta-analysis. J Affect Disord. 2010;126(3):335–48.
26. Walker J, Postma K, McHugh GS, Rush R, Coyle B, Strong V, et al.
Performance of the Hospital Anxiety and Depression Scale as a screening
tool for major depressive disorder in cancer patients. J Psychosom Res.
2007;63(1):83–91.
27. Mccullough ME, Emmons RA, Tsang JA. The grateful disposition: a
conceptual and empirical topography. J Pers Soc Psychol. 2002;82(1):112–27.
28. Herth K. Abbreviated instrument to measure hope: Development and
psychometric evaluation. J Adv Nurs. 1992;17(10):1251–9.
29. Salmon P, Manzi F, Valori RM. Measuring the meaning of life for patients
with incurable cancer: The life evaluation questionnaire (LEQ). Eur J Cancer.
1996;32A(5):755–60.
30. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-
Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76–82.
31. Stein AD, Lederman RI, Shea S. The Behavioral Risk Factor Surveillance
System questionnaire: Its reliability in a statewide sample. Am J Public
Health. 1993;83(12):1768–72.
32. Schwarzer R, Jerusalem M. Generalized Self-Efficacy scale. In: Weinman J,
Wright S, Johnston M, editors. Measures in health psychology: A user’s
portfolio Causal and control beliefs. Windsor, UK: NFER-NELSON; 1995. p. 35–7.
33. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics.
1982;38(4):963–74.
34. Hedeker D, Gibbons RD, Davis JM. Random regression models for
multicenter clinical trials data. Psychopharmacol Bull. 1991;27(1):73–7.
35. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of
treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59(10):877–83.
36. Bauman AE, Sallis JF, Dzewaltowski DA, Owen N. Toward a better
understanding of the influences on physical activity: The role of
determinants, correlates, causal variables, mediators, moderators, and
confounders. Am J Prev Med. 2002;23(2 Suppl):5–14.
37. Hedeker D, Gibbons R, Waternaux C. Sample size estimation for longitudinal
designs with attrition: Comparing time-related contrasts between two
groups. J Educ Behav Stat. 1999;24:70–93.
Montross-Thomas et al. BMC Palliative Care  (2015) 14:44 Page 7 of 8
38. Palinkas LA, Horwitz SM, Chamberlain P, Hurlburt MS, Landsverk J. Mixed-
methods designs in mental health services research: A review. Psychiatr
Serv. 2011;62(3):255–63.
39. Williams DG, Best AJ, Taylor DW, Gilbert JR, Wilson DMC, Lindsay EA, et al. A
systematic approach for using qualitative methods in primary prevention
research. Med Anthropol Q. 1992;4:391–409.
40. Glaser BG, Strauss A. The Discovery of Grounded Theory: Strategies
for Qualitative Research. New York, NY: Aldine de Gruyter; 1967.
41. Pierson CM, Curtis JR, Patrick DL. A good death: a qualitative study of
patients with advanced AIDS. AIDS Care. 2002;14(5):587–98.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Montross-Thomas et al. BMC Palliative Care  (2015) 14:44 Page 8 of 8
